News Releases
All Releases
View Summary Preclinical Data Presented at AACR Demonstrate Synergistic Anti-Tumor Effects of Peregrine Pharmaceuticals' Phosphatidylserine (PS)-Targeting Antibodies With Immune Checkpoint Inhibitors in Models of Melanoma and Breast Cancer
Apr 21, 2015
PDF 62.4 KB Add to Briefcase
View Summary Data Presented at AACR Demonstrate Peregrine Pharmaceuticals' Bavituximab Induces Immune Activation in PD-L1 Negative NSCLC Tumors
Apr 20, 2015
PDF 64.2 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2015 Annual Meeting
Apr 14, 2015
PDF 24.5 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces Promising Bavituximab Phase I Data Published in the Peer-Reviewed Journal Cancer Medicine in Advanced Metastatic Breast Cancer
Mar 31, 2015
PDF 24.4 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2015 Financial Results and Recent Developments
Mar 12, 2015
PDF 43.2 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
Mar 10, 2015
PDF 23.2 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals to Report Third Quarter Fiscal 2015 Financial Results After Market on March 12, 2015
Mar 5, 2015
PDF 20.5 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals to Present at the 27th Annual ROTH Conference
Mar 2, 2015
PDF 20.3 KB Add to Briefcase
View Summary Newly Presented Data Shows That Peregrine Pharmaceuticals' PS-Targeting Antibodies Significantly Enhance Anti-Tumor Activity of Immune Checkpoint Inhibitors PD-1 and CTLA-4 in Models of Breast Cancer and Melanoma
Feb 9, 2015
PDF 56.4 KB Add to Briefcase
View Summary Phase II Clinical Data of Peregrine Pharmaceuticals' Bavituximab in Combination With Sorafenib Presented at ASCO Gastrointestinal Cancers Symposium
Jan 16, 2015
PDF 19.9 KB Add to Briefcase
View Summary Data to Be Presented at 2014 San Antonio Breast Cancer Symposium Demonstrate Immune-Stimulatory Properties of Peregrine Pharmaceuticals' Bavituximab in Models of Breast Cancer
Dec 12, 2014
PDF 54.0 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2015 Financial Results and Recent Developments
Dec 10, 2014
PDF 71.4 KB Add to Briefcase
View Summary Avid Bioservices Announces Expansion of cGMP Manufacturing Capacity
Dec 10, 2014
PDF 17.2 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
Dec 9, 2014
PDF 13.6 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals to Report Second Quarter Fiscal 2015 Financial Results After Market on December 10, 2014
Dec 3, 2014
PDF 14.1 KB Add to Briefcase
View Summary Phase II Clinical Data Presented at SITC Annual Meeting Support Immunotherapeutic Mechanism of Action of Peregrine Pharmaceuticals' Bavituximab in Liver Cancer
Nov 10, 2014
PDF 21.0 KB Add to Briefcase
View Summary Data to Be Presented at the SITC Annual Meeting Support Synergy of PS-Targeting and Anti-CTLA-4 Immunotherapies to Enhance Anti-Tumor Treatments in Melanoma
Nov 7, 2014
PDF 56.6 KB Add to Briefcase
View Summary Promising Data Presented at the Chicago Multidisciplinary Symposium on Thoracic Oncology From an Investigator-Sponsored Trial of Peregrine Pharmaceuticals' Bavituximab in Combination With Pemetrexed and Carboplatin in Front-Line Non-Small Cell Lung Cancer
Oct 30, 2014
PDF 69.2 KB Add to Briefcase
View Summary Data to Be Published in the Journal of Immunology Research Support Phosphatidylserine (PS) as a Potential Target in Ebola Infection
Oct 15, 2014
PDF 22.1 KB Add to Briefcase
View Summary Data to Be Presented at CRI Immunotherapy Conference Show PS-Targeting Antibodies Enhance the Anti-Tumor Activity of Immune Checkpoint Inhibitors by Decreasing Levels of Myeloid Derived Suppressor Cells (MDSC) in the Tumor Microenvironment
Oct 6, 2014
PDF 19.0 KB Add to Briefcase
Showing 1-20 of 564 Page: 1 2 3 4 5 ... 29  Next 20
Add to Briefcase = add release to Briefcase
Print E-mail